Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biophytis Sa ADR (NQ: BPTS )

2.555 +0.045 (+1.77%)
Streaming Delayed Price Updated: 3:49 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biophytis Sa ADR

< Previous 1 2 Next >
Biophytis has Filed with the French National Authority for Health (HAS) an Application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19
Via ACCESSWIRE
Biophytis Presented Positive Results of Phase 2-3 COVA Study At The American Thoracic Society International Conference
Via ACCESSWIRE
Biophytis has Filed with the EMA for Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia
Via ACCESSWIRE
Successful Capital Increase for Biophytis with €2.3 million Raised
Via ACCESSWIRE
Biophytis Publishes its Financial Results for the First Half of 2022
Via ACCESSWIRE
Biophytis: Judgment of the Paris Court of Appeal of 17 January 2023 in the Case Between Biophytis and Negma Group Ltd
Via ACCESSWIRE
Biophytis Launches a Round of Fundraising for Approximately 2 Million Euros
Via ACCESSWIRE
Biophytis has Requested a Pre-Submission Meeting with the EMA for the Marketing Authorisation of Sarconeos (BIO101) for the Treatment of COVID-19
Via ACCESSWIRE
Biophytis Strengthens its Management Team
Via ACCESSWIRE
Biophytis Announces Receipt of Nasdaq Notice
Via ACCESSWIRE
Biophytis Regains Compliance with NASDAQ Minimum Bid Price Requirement
Via ACCESSWIRE
Biophytis Announces 2022 Financial Results and 2023 Perspectives
Via ACCESSWIRE
Biophytis: Results of the Combined General Meeting on April 17, 2023
Via ACCESSWIRE
Biophytis: The Combined General Meeting Will Be Held on Second Call on April 17, 2023
Via ACCESSWIRE
Biophytis: Biophytis Presented Sarconeos (BIO101) As A Possible Treatment Candidate for Long COVID After Hospitalization During The 13th Annual International Conference on Frailty and Sarcopenia Resea
Via ACCESSWIRE
Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program
Via ACCESSWIRE
Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference
Via ACCESSWIRE
Biophytis Announces the Signature of a Master Service Agreement With Intsel Chimos, a Pharmaceutical Company That Will Operate Sarconeos (BIO101) in France for the Treatment of Severe Forms of COVID-19
Via ACCESSWIRE
Biophytis Initiates the Regulatory Process for an Early Access Authorization in France from the French National Authority for Health (HAS) for the Treatment with Sarconeos (BIO101) of Severe Forms of COVID-19
Via ACCESSWIRE
Biophytis To Host a Combined General Shareholder’s Meeting on March 30, 2023
Via ACCESSWIRE
Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19
Via ACCESSWIRE
Biophytis To Take Appropriate Measures After Receiving Nasdaq Deficiency Notice
Via ACCESSWIRE
Biophytis Announces Its Participation in Two Major Investor Conferences in January, In the United States and In France: The JP Morgan Healthcare Conference and The Invest Securities Biomed
Via ACCESSWIRE
Biophytis Organises a Webcast with Key Opinion Leaders (KOL) On the Phase 2-3 Cova Study Results of Sarconeos (Bio101) In the Treatment of Pneumonia in Covid-19 Patients at Risk of Respiratory Failure
Via ACCESSWIRE
Biophytis Reports Positive Post-hoc Analysis of The Phase 2-3 COVA Clinical Study Strongly Supporting Therapeutic Potential of Sarconeos (BIO101) In COVID-19
Via ACCESSWIRE
Biophytis Publishes Its Key Financial Figures As at 30 June 2022, Announces a Restatement of the Financial Statements Published As of December 31st, 2021 and Provides an Update on the Operational Milestones
Via ACCESSWIRE
Biophytis Announces Receipt of Nasdaq Notice
Via ACCESSWIRE
Biophytis Participates in H.C. Wainwright 24th Annual Global Investment Conference
Via ACCESSWIRE
The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd
Via ACCESSWIRE
Biophytis Announces Very Promising Top Line Results of its Phase 2-3 COVA Clinical Study in COVID-19-Related Respiratory Failure
Via ACCESSWIRE
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.